Safety & Toxicity

microscope_close.jpg
 

Glauconix BiosciencesTM fills the need for assays that can provide relevant insight into safety and toxicity issues early in the drug development pipeline.  This extends beyond the development of ophthalmic therapeutics and across the full spectrum of new drugs.  Increase in IOP is a red flag that should be recognized very early on in the discovery process.  A number of widely prescribed drugs today are known to increase IOP as a side effect, and new alternatives should be readily sought.  Ocular safety and toxicity testing extends beyond pharma to the wider range of chemicals, additives and compounds that can impact human health.